KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2025)

Vir Biotechnology's Cash & Equivalents history spans 8 years, with the latest figure at $232.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 4.14% year-over-year to $232.2 million; the TTM value through Dec 2025 reached $232.2 million, up 4.14%, while the annual FY2025 figure was $232.2 million, 4.14% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $232.2 million at Vir Biotechnology, up from $211.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $963.7 million in Q3 2022 and bottomed at $6.1 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $217.0 million (2024), against an average of $312.9 million.
  • The largest annual shift saw Cash & Equivalents soared 15667.92% in 2022 before it crashed 98.44% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $8.6 million in 2021, then skyrocketed by 9774.69% to $848.6 million in 2022, then plummeted by 98.44% to $13.3 million in 2023, then skyrocketed by 1580.34% to $222.9 million in 2024, then increased by 4.14% to $232.2 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Cash & Equivalents are $232.2 million (Q4 2025), $211.1 million (Q2 2025), and $222.9 million (Q4 2024).